Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No worries, I threw that in there just to cover all the bases. People may remember reading about a 50/50 split but not recall the context.
Can confirm all the revenue should be going to ENZC, based on the PR's and disclosures I've seen. Afaik they'd account for the revenue on the ENZC books even if they manage operations through a subsidiary.
I wonder if the confusion comes from the recent disclosure that quoted the following:
All outstanding debt of the Company flowed to its subsidiary, now known as Robustomed, Inc. This means there are no outstanding convertible debt pieces of ENZC common equity, and that has been the case since November 30, 2020.
https://www.otcmarkets.com/otcapi/company/financial-report/323613/content
On May 12, 2021, the Company granted a distributorship license to a European pharma entity giving it the right to distribute the Company's anti-HIV-1 therapeutic ITV-1 in the countries of India, Pakistan, UAE, Indonesia, Philippines, Nigeria, Benin and Togo, Kenya, Tanzania, Rwanda, Libya, Uganda, North Sudan, Egypt, Morocco, and Tunisia. The Licensing Entity is the owner of a pharmaceutical plant in Eastern Europe. Pursuant to the Agreement, Enzolytics will receive $1 Million USD and 50% ownership in the Licensing Entity valued at $8 Million. The License is granted with a commitment by the Licensee to sale and distribute the ITV-1 therapeutic in the Licensed Territory. In addition, the Licensing Entity has invested $2 Million USD in the Company in exchange for Company Preferred Series E stock bringing to the Company $3 Million in cash plus a 50% ownership in the Licensing Entity. This agreement will result in establishing a committed partner for sale and distribution of the Company's ITV-1 therapeutic in the Licensed Territory as well as 50% ownership in Licensee and its profit derived from sales in the Licensed Territory.
Page 13 of the 2021 Annual Disclosure https://www.otcmarkets.com/otcapi/company/financial-report/325767/content
It's not a big deal as long as Synergy 11 can make a great website. I really don't care who builds the website, as long as it's professional and functional.
Synergy 11 might be an NPI subcontractor or affiliate, else I'm a little confused why NPI isn't handling the web presence since they were the (more established looking) firm we were told ENZC was using for IPF Immune marketing, retail and distribution. At the end of the day I'm glad to see ENZC making this progress one way or another.
Just looking into who they're working with since it apparently wasn't NPI doing the site in-house. It's progress - ENZC has an IPF Immune website now and yesterday they didn't. :)
A margarita sounds nice! Maybe this weekend.
It isn't always what it seems. If they did a promo page for the Air Force annual toy drive they could technically put the logo on their site. Their other clients appear to include local dentists, a local law firm and a presumably local car dealership.
That is one beautiful cured monkey! :) haha
Great info, thanks.
When I clicked the Find a Store Near You link on https://enzolyticstherapeutics.com/buy-now/ I get routed to a walmart 3rd party product page for a Bloom Beauty Essence "Skin Care Drink" that's "Sold and shipped by Nutritional Products International". Looks like maybe something the developers left in the website prototype to show how it works. Kinda sloppy work for a public debut, but it's something!
I think it's a leap to conclude ENZC has a store-shelves deal with walmart at this time. That said, NPI is already set up with walmart as a marketplace seller, & already making sales on other products, so ENZC has its foot in the door for that at least.
Here's NPI's seller profile page
https://www.walmart.com/seller/101032123?itemId=951069027&pageName=item
Here's info on Synergy Eleven, ENZC's web developers:
https://synergy11.marketing/
https://www.synergyeleven.com/
(both URLs lead to same site)
https://www.instagram.com/synergyeleven/?hl=en
352 followers
https://twitter.com/synergyeleven
87 Following
https://www.facebook.com/synergyeleven
559 people follow this
They look pretty small-time, but have a few notable names in their client list screencapped below. Web traffic and follows don't necessarily matter since this is a specialty service, but I'm including that here for completeness. The new https://enzolyticstherapeutics.com/ site looks like something a non-technical professional could throw together on Squarespace in a day, building out the site for dedicated ecommerce takes some more skilled work. Not sure about the 433 Plaza Real address listed as contact info, that seems to be a business complex about 20 minutes from the Synergy 11 contact address.
Glad to see an official product website, and ENZC still has a ways to go with it! Having a landing page is very important since then ENZC can maintain a list of selling points, retailers, contact info, product news, etc. It's a good early step even without built in ecommerce. I'm a little surprised NPI wasn't handling the web presence.
Nice to know, thanks!
Will be interesting to see how the market responds to knowing a fixed PR date. I've seen this kind of thing play out before as a "sell the news" opportunity after a nice run up. Should bring some extra buzz for this ticker either way.
Great catch, that's very interesting info.
Not necessarily a flag, because of the categorizations involved.
From the amended and original filings, respectively:
Amended https://www.otcmarkets.com/otcapi/company/financial-report/327646/content
Original https://www.otcmarkets.com/otcapi/company/financial-report/275843/content
Looks like the "Total current assets" around $560k was pretty close for both filings, give or take about $8k. The extra $20 Million from the original filing was because of "Total other assets" which was mostly "Intangible assets" and "Investment in Subsidiaries" which are suspicious line items for an unaudited pinkie recently trading in the trips. Not surprised early unaudited ENZC would think it proper to report those, and that QB-grade auditors would want to nix those, going forward. It would be hard to provide a fair valuation of intangible things like IP.
Page 5 of the amended filing under "Merger Agreement" talks a bit more about ENZC subsidiaries. Looks like investments were made to create two new subsidiaries to acquire IP. I'd think ENZC would want to highlight this activity in its financials since it was a positive thing, but probably accounted it incorrectly.
You're right that we have no partnership financing details. Can't say the claims ENZC is paying Samsung are true, nor false, from the info we have today.
It doesn't particularly matter either, imo, since having Samsung be the CDMO is about as ideal a partnership for successfully producing these mAbs as we could wish for. ENZC needs the mAbs for trials which is part of the path to future revenue, so it's great to see them taking this step with Samsung, whoever's paying for it.
It's anyone's guess. It was confusing to see no additional revenue in the following quarters as well.
Maybe it was one of:
- Something they rebucketed in the annual report under "Cash flows from financing activities".
- Something they shouldn't have reported at all, that an auditor addressed.
- A line item they accidentally overlooked for the annual report.
- Numbers from a deal that later fell apart.
- False information to prop up the stock in Q3 and Q4. (Hopefully not.)
We don't really know! Where it went is a good question, and it seems risky to jump to a conclusion on the limited info we have today.
They did report $200k in licensing revenue in the Q2'21 quarterly. Not sure what happened to it though. That's an unaudited document as well.
See page 2:
https://www.otcmarkets.com/otcapi/company/financial-report/297979/content
Would love to hear the answer to this, but if it is indeed the lawsuit holding things up, they would probably keep quiet since Savov could then make things worse by knowing he controls their timeline.
Wild guess, but if uplisting comes with new reporting requirements, ENZC may be dragging its feet so it can take certain actions now without extra accountability / layers of red tape. Especially if they're finalizing new partnerships or other important deals. Once they're QB, they have to tell us everything in a timely manner. See pages 8-9 under "Interim Event Disclosure" of this document:
https://www.otcmarkets.com/files/OTCQB_Standards.pdf
The same standard highlights how important it is that they get to QB, so we can get timely reporting on any bad news too.
Just completed a large head and shoulders on the hourly chart. This is usually bearish, though I think ENZC will trade sideways for awhile before it dips much lower. Current trading is using 200 hour moving average line (dark blue) as support.
https://www.investopedia.com/terms/h/head-shoulders.asp
Here's hoping for a strong website launch or other news this week to kick this back up!
Intraday hourly:
Some charts perspective:
I was away the whole weekend in a work crunch. Just getting back to this today. Looks pretty red.
Here are some chart observations I just made, for anyone curious.
Disclaimers:
- All charts are intraday since today is still ongoing.
- If if you don't think charts apply to this ticker, just ignore 'em. :)
- I'd love your feedback!
- News generally trumps charts.
Starting with the weekly chart, there's a definite pattern here. Every time ENZC gets near a low, it dead-cat bounces to the bollinger bands midline on higher volume. Then the market says "No" the next week, and we slowly ride it down another level.
This time, the bollinger bands are narrow, and MACD is a lot closer to retesting a crossover into green. It looks to me that, barring big news, we'll have at least one more cycle of this pattern before we have enough oomph to get into the top bollinger band. The setup IS there for that to happen this or next week and skip a longer wait, but with today's action I'm pretty skeptical.
On the hourly chart, if you look closely there's a head-and-shoulders reversal pattern that formed up Friday, completing the pattern in a decisive way with today's movement. Hourly RSI is reset to a cool, neutral 44ish and hourly MACD is about to either reflect upward or crossover downward.
Today's dip looks too severe to be profit taking, so this may get a mini-dead-cat bounce at the 200 hour moving average (dark blue line) to form the right shoulder of a wider head & shoulders, and if that pattern materializes we'll probably be seeing .06's and .05's again when that H&S reaches its conclusion.
This next chart is for volume analysis. Each pair of yellow bars is a daily session and the bright blue bars are the point of highest volume. Pink line is VWAP and generally things are bullish above it, bearish below it.
The Oscillator at the bottom of the image shows bears trading way outside the neutral zone in today's session. Interestingly, this is how aggressively bears were willing to sell when we thought someone was maybe dumping shares in the weeks before. Given the volume today at already almost 10 mil, I wouldn't be surprised if somebody is dumping shares to profit off the recent run, along with some retail panic selling.
Trading in the latest session is far below VWAP so bears are firmly in control, though this chart is intraday.
A lot of profit taking happening at these levels. It's touching the top of the daily bollinger band - often in that scenario price reflects back down to the midline over the next few days before bouncing later to retest the top. This is already a high volume day so maybe we'll just blow right out the top instead. Should be choppy trading for awhile while the market decides, & hopefully MMs don't put a finger on the scale.
No serious sell pressure yet. Unless bears step back in or someone dumps new shares, bulls are just taking a break. My guess is we get a green Friday.
The PR may have had some new info about Samsung's progress with mAbs: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168659537
And now the news out of Africa today: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168685195
Most of the volume the last three daily sessions is happening at the higher end of our price range (bold blue bars are high volume prices). Trading is currently above VWAP (the pink line) which suggests bulls are currently in control.
On the Volume Zone Oscillator we can see where bears tested the waters and the market rejected.
Intraday chart (today's still in progress)
Here are some of the ITV-1 players:
Scendea - regulatory and "clinical development plan"
Danhson - product production
Clinic Design - clinical trials
https://finance.yahoo.com/news/enzolytics-reports-engagement-scendea-usa-123000633.html
Afaik some of the debt comes from years in the past before ENZC was ENZC, and also some from the early years of ENZC. I assume the $29.5 Million includes old debt currently held in ENZC subsidiaries as well, though maybe not:
The Company has incurred an operating losses since inception and as of December 31, 2020, the Company has incurred accumulated deficit of $29,533,234.
http://www.otcmarkets.com/otcapi/company/financial-report/327646/content
Lucky! XD And congrats!
Weekly chart:
In case you missed it, DOGONE's got ya too: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168671211
This chart is intraweek, so the latest candle isn't done forming yet.
The market's currently resisting falling below that 200 week moving average (dark blue line). Note the latest two candles -- red touching the bottom bollinger band edge (dashed pink line) followed by a decisive green candle (so far) to bring us back into the band.
This price range would be a great turning point for ENZC to move into a more bullish trading season, starting with a test of the midline near .085 and the high band edge near .12. The nearest low is also close enough to count as a double bottom with the low from December 2021, which is a bullish chart setup if we can continue moving higher from here.
If it flounders tomorrow and Friday and we get an aggressive red week next week, that's when a bigger breakdown could happen. Personally I don't see it breaking down with all the recent positive buzz. This week or next would be a good time for Chandra to throw us some bigger news to help it trend upward.
Good info, thanks. Have a great day as well!
I have a similar concern. I'm glad ENZC is pursuing EMA approval as well. If they got stuff approved in Europe it would put a lot of pressure on American regulators to also approve.
Thanks! GLTU also!
I missed that there was a falling wedge in play.
+ Price has been riding the top of the hourly bollinger band all day.
+ Hourly MACD looks better than it's looked since January. (I cut it off on this chart for clarity.)
-- We're approaching one of the profit targets for that wedge around ~$0.075 and the 200 hour moving average, so it'd make sense to see some resistance soon.
-- Hourly RSI is in breakout and breakouts/breakdowns don't usually last long before market correction.
Intraday hourly:
Dashed pink and bold light blue 20 hour moving average line are bollinger bands.
Dark blue is 200 hour moving average.
7,922,397 shares traded so far. At the current highest volume price of 0.0641 that's about half a million dollars give or take. This was way oversold recently and without the same bearish pressure it could be retail responding bullishly to Chandra's recent bold tweets.
Curious to see if we get a power hour, or if big sell volume swoops in late, or if trading gets maneuvered into a specific chart position by end of day. Been pretty solid green for a newsless Tuesday this far.
Thanks for the update!
Series A is a control block, they'll not dump them. (They actually have no conversion rights.)
Where are your other numbers coming from?
I posted this over the weekend, it includes everything I could find on all classes of their shares. (Scroll down to about the middle.) Series E appears to be an unknown and very badly accounted for in their filings. They do call them "convertible" though.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168639909
See Also https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168641060
Haha I was wondering where the forward looking statements disclaimer went, assumed it was overlooked by a bot or site admin reposting the PR.
They raised $2 Million selling Series E Convertible Preferred and $950,000 in sales of subscribed Series C Convertible Preferred Stock in mid 2021. Diluted in very late March or early April 2022 and are probably finished dumping the bulk of 32.5 Million shares. NPI is doing the marketing for Enzoimmune Active and represented them at the retail convention in late March. Let me know if you want links to the filings, I don't have them handy at the moment.
It's a pretty bold claim. Along with the long list of juicy hashtags. He's backing himself into a corner with tweets like that, but also imagine the pop if ENZC actually delivers on a bunch of these at once. (Which is, of course, how pumping generally works!)
It's due for a dead cat bounce being this oversold. Give investors any reason and it could be pretty bouncy. Dry powder ready. :)
"ENZC is a coiled spring compressed and pushed together: It contains a lot of potential energy that will explode instantly with multiple catalysts. #ENZC #AUDIT #IPFIMMUNE #REVENUE #TVCOMMERCIAL #ITV1 #AI #HIV #SARSCOV2 #MAB #Equity #UPLIST #partnerships"
ENZC is a coiled spring compressed and pushed together: It contains a lot of potential energy that will explode instantly with multiple catalysts. #ENZC #AUDIT #IPFIMMUNE #REVENUE #TVCOMMERCIAL #ITV1 #AI #HIV #SARSCOV2 #MAB #Equity #UPLIST #partnerships
— Gaurav Chandra M.D. (@drgauravchandra) April 25, 2022
Very astute, I hope you're right!
Also I don't mind a rehash PR from time to time vs radio silence. Lets us know that things are status quo which quells some of the speculation they might be going backward.
Interesting, perhaps it's an anomaly or setting in your charting software.
That Investopedia link says "The A/D indicator is cumulative, meaning one period’s value is added or subtracted from the last" which implies that if you can re-run the calculation for a prior day, it should provide the same result.
But maybe the software is only running the math so far into the past, like 2 years cutoff or something. Then the historic numbers would change with every new day.
On TD Ameritrade's Thinkorswim I'm seeing +1,270,001,680 for ENZC today setting timeframe to Max. If I change the timeframe to something smaller I get a totally different number for Acc/Dist.
Here it is for the last year of day-length trading sessions. LOTS of distribution.
Context:
Agreed, 30 million in revenue (or new private financing) is totally achievable and quickly, if ENZC makes it big with pretty much any of its pipelined tech. Some of the liabilities can't simply be paid off; it seems lots of parties hold various notes with options that must be honored if the owners choose to exercise them. But if ENZC hits big and the market gets desperate for a piece of the pie, some conversion/dilution on the way up is healthy and sustainable. Where this flounders is if ENZC delivers zero/mediocre results instead, runs out of operating cash, or badly times major restructuring like a R/S. Good luck to you as well!
There are other ways to reduce your exposure as well, if you feel that is the right move. I sold a bunch of ENZC in September, October, Novemeber 2021 that was double digits in the red. Used the cash during holiday sales to buy deeply discounted software and art assets I needed for my business. The extra buying power I gained during the sales stretched my dollars with zero of the stock market risk & micromanaged trades, quickly offsetting the ENZC loss. Capital loss was claimable on 2022 and future taxes as well.
ENZC could still run anytime, so I set trading alarms, check in often, and keep dry powder ready. I've also kept a core that's currently down about 54% and I'm okay with losing this all.
This is not investing advice, just encouragement to stay creative and manage your risk!
ENZC has done a decent job diversifying opportunities and networking with potential partners. It has human and animal mAbs in the works, stuff happening in Africa, an upcoming product that might generate some sizeable revenue, etc. I wouldn't write them off at all, though they have some real hurdles to cross in the days ahead.
Glad you found it useful and while I tried to document the heck out of it, I do hope people pick it apart with stuff I overlooked. It's a very mixed bag, could be better and could be worse. Definitely has some risk and might require a lot more patience in days ahead. It's also a company pursuing disruptive technology that might just change the world.
Nah I'm super into it, (or the idea of it?) but very skeptical. Trying to know what I'm dealing with before I put too much money at risk.